Dr. Willis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd., Unit 0426
Houston, TX 77030- Is this information wrong?
Summary
- Dr. Jason Willis is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including University of Texas M.D. Anderson Cancer Center and Harris Health System. He received his medical degree from Weill Cornell Medicine and has been in practice 2 years. He specializes in cancer genetics/cancer risk assessment and gastrointestinal cancer and is experienced in pancreatic cancer.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
Weill Cornell MedicineClass of 2014, M.D.
Certifications & Licensure
FL State Medical License 2021 - Present
WA State Medical License 2023 - 2025
MS State Medical License 2023 - 2024
TX State Medical License 2018 - 2024
AL State Medical License 2023 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Start of enrollment: 2019 Jul 22
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling.Wang, X., Dasari, A., Shen, J., Drusbosky, L., Johnson, B., Morris, V., Raghav, K., Lee, M., Huey, R., Parseghian, C., Willis, J., Wolff, R., Overman, M., Kopetz, S.> ;Cancers. 2024 Feb 9
- 3 citationsImpact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl, Paul Edelkamp, Kristin Alfaro-Munoz, Ray Chacko, Jennifer Peterson, Brandon G Smagl...> ;NPJ Precision Oncology. 2024 Feb 3
- Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.Simmons, K., Thomas, J., Ludford, K., Willis, J., Higbie, V., Raghav, K., Johnson, B., Dasari, A., Kee, B., Parseghian, C., Lee, M., Le, P., Morelli, M., Shen, J., Ben...> ;Cancer Research Communications. 2023 Dec 11
- Join now to see all
Journal Articles
- Colorectal Premalignancy Is Associated with Consensus Molecular Subtypes 1 and 2L M Ellis, P M Lynch, J A Willis, S Kopetz, Annals of Oncology
Press Mentions
‘It’s Striking’: MD Anderson Researcher Investigates Cause of Racial Disparities in Colon CancerMarch 5th, 2022- Breaking Barriers to Colorectal Cancer Care for Black PatientsNovember 10th, 2023
Professional Memberships
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
